Advanced search
Publication Cover
Cancer Investigation Volume 21, 2003 - Issue 5
Submit an article Journal homepage
59
Views
11
CrossRef citations to date
0
Altmetric
Original

Weekly Paclitaxel Infusion as Salvage Therapy in Ovarian Cancer

Original Article

David M. Boruta II Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, North CarolinaUSA
, M.D.,
Wesley C. Fowler Jr., Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, North CarolinaUSA
, M.D.,
Paola A. Gehrig Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, North CarolinaUSA
, M.D.,
John F. Boggess Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, North CarolinaUSA
, M.D.,
Leslie A. Walton Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, North CarolinaUSA
, M.D. &
Linda Van Le Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The University of North Carolina, Chapel Hill, North CarolinaUSA
, M.D.
Pages 675-681 | Published online: 10 Aug 2003

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

M. Montana, C. Ducros, P. Verhaeghe, T. Terme, P. Vanelle & P. Rathelot. (2011) Albumin-Bound Paclitaxel: The Benefit of This New Formulation in the Treatment of Various Cancers. Journal of Chemotherapy 23:2, pages 59-66.
Read now
Soon Thye Lim & Alexandra M. Levine. (2005) Angiogenesis and hematological malignancies. Hematology 10:1, pages 11-24.
Read now

Articles from other publishers (9)

David J. Pinato, Janet Graham, Hani Gabra & Rohini Sharma. (2013) Evolving concepts in the management of drug resistant ovarian cancer: Dose dense chemotherapy and the reversal of clinical platinum resistance. Cancer Treatment Reviews 39:2, pages 153-160.
Crossref
Robert L. Coleman, William E. Brady, D. Scott McMeekin, Peter G. Rose, John T. Soper, Samuel S. Lentz, James S. Hoffman & Mark S. Shahin. (2011) A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology 122:1, pages 111-115.
Crossref
Richard D. Baird, David S. P. Tan & Stan B. Kaye. (2010) Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nature Reviews Clinical Oncology 7:10, pages 575-582.
Crossref
Michael G. TenerielloPaul C. TsengMark CrozierCarlos EncarnacionKenneth HancockMark J. MessingKristi A. BoehmAlicia WilliamsLina Asmar. (2009) Phase II Evaluation of Nanoparticle Albumin–Bound Paclitaxel in Platinum-Sensitive Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer. Journal of Clinical Oncology 27:9, pages 1426-1431.
Crossref
M. Linch, F. Stavridi, J. Hook, Y. Barbachano, M. Gore & S.B. Kaye. (2008) Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer. Gynecologic Oncology 109:1, pages 27-32.
Crossref
Howard D. Homesley, Nathan P. Meltzer, Lucybeth Nieves, Luis Vaccarello, George S. Lowendowski & Al A. Elbendary. (2008) A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. International Journal of Clinical Oncology 13:1, pages 62-65.
Crossref
Britta Stordal, Nick Pavlakis & Ross Davey. (2007) A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship. Cancer Treatment Reviews 33:8, pages 688-703.
Crossref
Michele L. Donato, Xipeng Wang, John J. Kavanagh & David M. Gershenson. 2006. Gynecologic Cancer. Gynecologic Cancer 188 206 .
M.E.L. BURG, A. van der GAAST, I. VERGOTE, C.W. BURGER, H.C. van DOORN, R. de WIT, G. STOTER & J. VERWEIJ. (2005) What is the role of dose-dense therapy?. International Journal of Gynecological Cancer 15:s3, pages 233-240.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.